Cerus - CERS Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares.
View CERS analyst ratings or view top-rated stocks.

3 brokerages have issued 1-year price targets for Cerus' stock. Their CERS share price forecasts range from $3.75 to $6.00. On average, they expect the company's share price to reach $4.88 in the next year. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS shares have decreased by 16.2% and is now trading at $3.06.
View the best growth stocks for 2023 here.

Cerus saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,280,000 shares, an increase of 11.7% from the December 31st total of 5,620,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 4.8 days.
View Cerus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our CERS earnings forecast.

Cerus Co. (NASDAQ:CERS) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The biotechnology company earned $39.57 million during the quarter, compared to analyst estimates of $39 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%.

Cerus updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (8.94%), Assenagon Asset Management S.A. (1.41%), Stephens Inc. AR (0.36%), Exchange Traded Concepts LLC (0.14%) and Bouvel Investment Partners LLC (0.13%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CERS stock can currently be purchased for approximately $3.06.

Cerus (NASDAQ:CERS) has a market capitalization of $542.91 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 631 workers across the globe.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.